OptimizeRx Reports First Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 12 2026
0mins
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy OPRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on OPRX
Wall Street analysts forecast OPRX stock price to rise
7 Analyst Rating
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 6.080
Low
17.00
Averages
24.33
High
32.00
Current: 6.080
Low
17.00
Averages
24.33
High
32.00
About OPRX
OptimizeRx Corporation is a healthcare technology company. The Company’s platform combines artificial intelligence (AI)-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT) to deliver timely, relevant, and hyper-local engagement. Its DAAP generates dynamic audiences with predictive analytics via machine learning methods. MNT creates consumer audiences using a privacy-first process. Its principal solutions include Audience Development: DAAP and MNT, Audience Profiling: Profiler, Audience Activation and Media Execution, Pharmacy Alerts, and Financial Messaging. Its Financial Messaging provides prescribers visibility to branded copay offers for patients directly within their electronic health record (EHR) systems and electronic prescribing (ERx) platforms. Its platform consists of a unified data intelligence technology stack, multiple cloud-based data warehouses, and in-house applications and application programming interface layers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
OptimizeRx Launches CopayCue to Enhance Prescription Transparency
- Product Launch: OptimizeRx has introduced CopayCue, which leverages real-time HCP prescribing intent data to deliver brand savings information directly within the e-prescribing workflow, aiming to enhance transparency for physicians at the point of prescribing and improve patient adherence to medications.
- Addressing Affordability Issues: With 43% of U.S. adults reporting they have not taken their medications as prescribed due to cost, CopayCue is expected to significantly reduce the number of patients abandoning prescriptions due to cost, potentially alleviating the estimated $300 billion annual cost of non-adherence to the U.S. healthcare system.
- Increasing Prescription Conversion Rates: The implementation of CopayCue has demonstrated a prescription lift of 4-5% over EHR banners alone, with standalone programs achieving an average lift of 11.5%, which will directly drive market performance for life sciences brands and enhance patient access to therapies.
- Strategic Partnerships and Market Impact: By collaborating with over 400 electronic health record and e-prescribing platforms, OptimizeRx ensures that brand savings offers are activated at critical prescribing moments, thereby enhancing brand awareness and customer loyalty, further solidifying its leadership position in the healthcare technology sector.
See More
OptimizeRx Launches AI-Powered Audience Builder Tool
- Technological Innovation: OptimizeRx's launch of the Natural Language Audience Builder (NLAB) combines real-world evidence with proprietary data, enabling life sciences companies to more effectively create and manage custom healthcare provider (HCP) audiences within media planning platforms, thereby enhancing marketing precision and efficiency.
- Market Demand Response: NLAB allows marketers to build and refine custom NPI lists without code or analyst support, addressing the urgent need for rapid and flexible audience building, which is expected to significantly enhance clients' market responsiveness.
- Revenue Growth Potential: By embedding audience intelligence into DSP workflows, OptimizeRx not only strengthens its role as an infrastructure partner but also creates new recurring revenue streams, further solidifying its market position within the healthcare ecosystem.
- Future Integration Plans: NLAB is expected to be available for platform integration in August 2026, bundled with OptimizeRx's authenticated point-of-care inventory, marking the company's ongoing efforts to drive intelligence in healthcare marketing and assist clients in achieving more efficient advertising deployment.
See More
OptimizeRx Partners with DeepIntent to Enhance Advertising Efficiency
- EHR Network Integration: OptimizeRx has partnered with DeepIntent, making it the first demand-side platform to integrate OptimizeRx's electronic health record (EHR) network into its advertising platform, which is expected to enhance advertising activation efficiency for life sciences marketers and improve provider engagement.
- Clinical Workflow Programmatic Buying: This integration allows life sciences marketers to access OptimizeRx's authenticated EHR inventory directly within the DeepIntent platform, enabling them to reach healthcare providers more effectively at critical clinical decision moments, thereby increasing the relevance and timeliness of their advertising.
- Response to Market Demand: The collaboration reflects a growing demand for privacy-safe advertising solutions, with OptimizeRx's CEO stating that the integration will make it easier for clients to activate validated EHR inventory on a trusted platform, enhancing the effectiveness of their advertising efforts.
- Future Development Strategy: OptimizeRx plans to expand programmatic access to its authenticated EHR network through additional demand-side partnerships over time, aiming to make clinically aligned point-of-care media more accessible within modern healthcare advertising workflows, thus driving overall industry growth.
See More
OptimizeRx Exceeds Expectations with Strong Q1 Growth
- Performance Exceeds Expectations: OptimizeRx Corp (NASDAQ:OPRX) surpassed consensus estimates for both revenue and net income in Q1 2026, demonstrating a robust 60% growth in its AI-driven DApp solution, indicating strong product-market fit and customer adoption, which may enhance market share further.
- Revenue Structure Shift: The company is transitioning its revenue mix towards subscription models, a strategy that not only improves revenue visibility and predictability but also presents significant growth opportunities with mid-tier and long-tail life science companies, potentially strengthening long-term competitiveness.
- Gross Margin Optimization: Through gross margin optimization initiatives, OptimizeRx anticipates achieving a gross margin of over 60% for the full year 2026, despite a 10% decline in Q1 revenue compared to the same period in 2025, as margin improvements may help alleviate pressures from revenue declines.
- Cautious Revenue Guidance: Due to macroeconomic factors and cautious budget allocations from clients, OptimizeRx has updated its revenue guidance for 2026, now expecting revenue between $95 million and $100 million, reflecting the company's clear understanding of future market uncertainties.
See More
OptimizeRx Q1 2026 Earnings Call Insights
- Revenue Decline: OptimizeRx reported Q1 2026 revenue of $19.8 million, a 10% decrease from $21.9 million in Q1 2025, primarily due to ongoing softness in contracted revenue linked to last year's most favored nation pricing dynamics and macroeconomic factors, impacting financial stability.
- Cost Optimization Measures: The company expects to reduce cash operating expenses by approximately $3 million annually through cost structure alignment, with an anticipated $1 million benefit in 2026, which will help improve profitability and cash flow.
- Platform Distribution Transformation: OptimizeRx is enabling demand-side platforms controlling over 80% of digital promotional dollars to connect directly to its proprietary EHR network, a strategic shift expected to enhance utilization and strengthen market competitiveness.
- 2026 Guidance Adjustment: The company revised its 2026 revenue outlook to a range of $95 million to $100 million, reflecting a cautious stance on future revenue, while maintaining adjusted EBITDA guidance at $21 million to $25 million, indicating ongoing focus on profitability.
See More
OptimizeRx Scheduled to Announce Q1 Earnings Results
- Earnings Announcement Date: OptimizeRx (OPRX) is set to release its Q1 2023 earnings report on May 12 after market close, with consensus EPS estimate at $0.00, reflecting a 100% year-over-year decline, and revenue estimate at $18.35 million, down 16.2% year-over-year, indicating significant challenges ahead for the company.
- Historical Performance Review: Over the past two years, OPRX has exceeded EPS estimates 88% of the time and revenue estimates 75% of the time, although recent estimate revisions suggest a cautious outlook from the market regarding its future performance.
- Estimate Revision Trends: In the last three months, EPS estimates have seen one upward revision and four downward revisions, while revenue estimates have experienced no upward revisions and six downward revisions, indicating a weakening confidence among analysts regarding the company's prospects.
- Long-term Outlook: OptimizeRx has set a revenue target of $109 million to $114 million for 2026 in its Q4 earnings report, and despite the cautious outlook driven by market shifts, the company is actively working to adapt to the new market environment to achieve growth.
See More
OptimizeRx Launches CopayCue to Enhance Prescription Transparency
- Product Launch: OptimizeRx has introduced CopayCue, which leverages real-time HCP prescribing intent data to deliver brand savings information directly within the e-prescribing workflow, aiming to enhance transparency for physicians at the point of prescribing and improve patient adherence to medications.
- Addressing Affordability Issues: With 43% of U.S. adults reporting they have not taken their medications as prescribed due to cost, CopayCue is expected to significantly reduce the number of patients abandoning prescriptions due to cost, potentially alleviating the estimated $300 billion annual cost of non-adherence to the U.S. healthcare system.
- Increasing Prescription Conversion Rates: The implementation of CopayCue has demonstrated a prescription lift of 4-5% over EHR banners alone, with standalone programs achieving an average lift of 11.5%, which will directly drive market performance for life sciences brands and enhance patient access to therapies.
- Strategic Partnerships and Market Impact: By collaborating with over 400 electronic health record and e-prescribing platforms, OptimizeRx ensures that brand savings offers are activated at critical prescribing moments, thereby enhancing brand awareness and customer loyalty, further solidifying its leadership position in the healthcare technology sector.
See More
OptimizeRx Launches AI-Powered Audience Builder Tool
- Technological Innovation: OptimizeRx's launch of the Natural Language Audience Builder (NLAB) combines real-world evidence with proprietary data, enabling life sciences companies to more effectively create and manage custom healthcare provider (HCP) audiences within media planning platforms, thereby enhancing marketing precision and efficiency.
- Market Demand Response: NLAB allows marketers to build and refine custom NPI lists without code or analyst support, addressing the urgent need for rapid and flexible audience building, which is expected to significantly enhance clients' market responsiveness.
- Revenue Growth Potential: By embedding audience intelligence into DSP workflows, OptimizeRx not only strengthens its role as an infrastructure partner but also creates new recurring revenue streams, further solidifying its market position within the healthcare ecosystem.
- Future Integration Plans: NLAB is expected to be available for platform integration in August 2026, bundled with OptimizeRx's authenticated point-of-care inventory, marking the company's ongoing efforts to drive intelligence in healthcare marketing and assist clients in achieving more efficient advertising deployment.
See More
OptimizeRx Partners with DeepIntent to Enhance Advertising Efficiency
- EHR Network Integration: OptimizeRx has partnered with DeepIntent, making it the first demand-side platform to integrate OptimizeRx's electronic health record (EHR) network into its advertising platform, which is expected to enhance advertising activation efficiency for life sciences marketers and improve provider engagement.
- Clinical Workflow Programmatic Buying: This integration allows life sciences marketers to access OptimizeRx's authenticated EHR inventory directly within the DeepIntent platform, enabling them to reach healthcare providers more effectively at critical clinical decision moments, thereby increasing the relevance and timeliness of their advertising.
- Response to Market Demand: The collaboration reflects a growing demand for privacy-safe advertising solutions, with OptimizeRx's CEO stating that the integration will make it easier for clients to activate validated EHR inventory on a trusted platform, enhancing the effectiveness of their advertising efforts.
- Future Development Strategy: OptimizeRx plans to expand programmatic access to its authenticated EHR network through additional demand-side partnerships over time, aiming to make clinically aligned point-of-care media more accessible within modern healthcare advertising workflows, thus driving overall industry growth.
See More
OptimizeRx Exceeds Expectations with Strong Q1 Growth
- Performance Exceeds Expectations: OptimizeRx Corp (NASDAQ:OPRX) surpassed consensus estimates for both revenue and net income in Q1 2026, demonstrating a robust 60% growth in its AI-driven DApp solution, indicating strong product-market fit and customer adoption, which may enhance market share further.
- Revenue Structure Shift: The company is transitioning its revenue mix towards subscription models, a strategy that not only improves revenue visibility and predictability but also presents significant growth opportunities with mid-tier and long-tail life science companies, potentially strengthening long-term competitiveness.
- Gross Margin Optimization: Through gross margin optimization initiatives, OptimizeRx anticipates achieving a gross margin of over 60% for the full year 2026, despite a 10% decline in Q1 revenue compared to the same period in 2025, as margin improvements may help alleviate pressures from revenue declines.
- Cautious Revenue Guidance: Due to macroeconomic factors and cautious budget allocations from clients, OptimizeRx has updated its revenue guidance for 2026, now expecting revenue between $95 million and $100 million, reflecting the company's clear understanding of future market uncertainties.
See More
OptimizeRx Q1 2026 Earnings Call Insights
- Revenue Decline: OptimizeRx reported Q1 2026 revenue of $19.8 million, a 10% decrease from $21.9 million in Q1 2025, primarily due to ongoing softness in contracted revenue linked to last year's most favored nation pricing dynamics and macroeconomic factors, impacting financial stability.
- Cost Optimization Measures: The company expects to reduce cash operating expenses by approximately $3 million annually through cost structure alignment, with an anticipated $1 million benefit in 2026, which will help improve profitability and cash flow.
- Platform Distribution Transformation: OptimizeRx is enabling demand-side platforms controlling over 80% of digital promotional dollars to connect directly to its proprietary EHR network, a strategic shift expected to enhance utilization and strengthen market competitiveness.
- 2026 Guidance Adjustment: The company revised its 2026 revenue outlook to a range of $95 million to $100 million, reflecting a cautious stance on future revenue, while maintaining adjusted EBITDA guidance at $21 million to $25 million, indicating ongoing focus on profitability.
See More
OptimizeRx Scheduled to Announce Q1 Earnings Results
- Earnings Announcement Date: OptimizeRx (OPRX) is set to release its Q1 2023 earnings report on May 12 after market close, with consensus EPS estimate at $0.00, reflecting a 100% year-over-year decline, and revenue estimate at $18.35 million, down 16.2% year-over-year, indicating significant challenges ahead for the company.
- Historical Performance Review: Over the past two years, OPRX has exceeded EPS estimates 88% of the time and revenue estimates 75% of the time, although recent estimate revisions suggest a cautious outlook from the market regarding its future performance.
- Estimate Revision Trends: In the last three months, EPS estimates have seen one upward revision and four downward revisions, while revenue estimates have experienced no upward revisions and six downward revisions, indicating a weakening confidence among analysts regarding the company's prospects.
- Long-term Outlook: OptimizeRx has set a revenue target of $109 million to $114 million for 2026 in its Q4 earnings report, and despite the cautious outlook driven by market shifts, the company is actively working to adapt to the new market environment to achieve growth.
See More
